Cell Medica
LONDON, February 10, 2011 - Cell Medica, a leading UK cellular therapeutics company that develops,
manufactures and markets cellular immunotherapy products for the treatment of
infectious disease and cancer, announces today that the first patient has
been treated in the CMV~ACE/ASPECT trial at University College Hospital
London.
LONDON, January 6, 2011 - Cancers
- Positive Results Already Seen in Current Clinical Development
- Significant Market Potential, Estimated to Exceed $1.0 billion
Cell Medica, a leading cellular therapeutics company which
develops, manufactures and markets cellular immunotherapy products for the
treatment of infectious disease and cancer, is pleased to announce an
exclusive license agreement and research collaboration with the Center for
Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas),
for the commercialization of an innovative cell-based treatment for cancers
associated with the oncogenic Epstein Barr virus (EBV).
